Akeso
cadonilimab(Akeso)은 Salivary Gland Carcinoma 표적 항체로, Metastatic HER2 Positive Gastroesophageal Junction Cancer 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 65건의 관련 임상이 등록되어 있습니다. 차별점: novel triple-combination conversion therapy, enriching treatment options for patients with potentially resectable or technica.
Salivary Gland Carcinoma
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Recruiting
bispecific antibody targeting PD-1 and CTLA-4) in combination with che
-driven
humanized mice
novel triple-combination conversion therapy, enriching treatment options for patients with potentially resectable or technica
checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review
cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and on-target off-tumor effects r
payload-driven ADCs, BsAbs provide a ready-to-use therapeutic format that simultaneously engages two antigens, offering distinc
biomarkers of cadonilimab in cervical cancer: a prospective observational study
escape, providing a new strategy for the treatment of CRC
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Akeso
cadonilimab(Akeso)은 Salivary Gland Carcinoma 표적 항체로, Metastatic HER2 Positive Gastroesophageal Junction Cancer 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 65건의 관련 임상이 등록되어 있습니다. 차별점: novel triple-combination conversion therapy, enriching treatment options for patients with potentially resectable or technica.
Salivary Gland Carcinoma
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Recruiting
bispecific antibody targeting PD-1 and CTLA-4) in combination with che
-driven
humanized mice
novel triple-combination conversion therapy, enriching treatment options for patients with potentially resectable or technica
checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review
cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and on-target off-tumor effects r
payload-driven ADCs, BsAbs provide a ready-to-use therapeutic format that simultaneously engages two antigens, offering distinc
biomarkers of cadonilimab in cervical cancer: a prospective observational study
escape, providing a new strategy for the treatment of CRC
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.